David Clever

3.6k total citations · 1 hit paper
20 papers, 1.4k citations indexed

About

David Clever is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, David Clever has authored 20 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Immunology, 10 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in David Clever's work include Immune Cell Function and Interaction (8 papers), CAR-T cell therapy research (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). David Clever is often cited by papers focused on Immune Cell Function and Interaction (8 papers), CAR-T cell therapy research (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). David Clever collaborates with scholars based in United States, United Kingdom and France. David Clever's co-authors include Nicholas P. Restifo, Robert Eil, Christopher A. Klebanoff, Madhusudhanan Sukumar, Rahul Roychoudhuri, Douglas C. Palmer, Zhiya Yu, Jenny H. Pan, Tori N. Yamamoto and Suman K. Vodnala and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

David Clever

18 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ionic immune suppression within the tumour microenvironment limits T cell effector function

2016 489 citations Robert Eil, Suman K. Vodnala et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Clever United States	11	778	714	518	190	148	20	1.4k
Claudia Paret Germany	20	818 1.1×	938 1.3×	942 1.8×	213 1.1×	116 0.8×	43	1.9k
Daniel W. Beury United States	9	1.2k 1.5×	853 1.2×	480 0.9×	199 1.0×	135 0.9×	10	1.8k
Wendy Béguelin United States	20	402 0.5×	555 0.8×	763 1.5×	191 1.0×	58 0.4×	34	1.4k
Yingzi Ge Germany	16	665 0.9×	600 0.8×	419 0.8×	70 0.4×	61 0.4×	22	1.2k
Jason Hatakeyama United States	13	702 0.9×	390 0.5×	678 1.3×	176 0.9×	83 0.6×	17	1.3k
Shashank J. Patel United States	10	664 0.9×	608 0.9×	644 1.2×	169 0.9×	149 1.0×	20	1.4k
Elena Jachetti Italy	18	680 0.9×	532 0.7×	581 1.1×	374 2.0×	99 0.7×	35	1.3k
John A. Zebala United States	14	795 1.0×	787 1.1×	457 0.9×	98 0.5×	92 0.6×	41	1.5k
Fátima Valdés‐Mora Australia	19	334 0.4×	415 0.6×	975 1.9×	277 1.5×	108 0.7×	31	1.5k
Serena Zilio Italy	13	1.2k 1.6×	674 0.9×	294 0.6×	87 0.5×	94 0.6×	16	1.5k

Countries citing papers authored by David Clever

Since Specialization

Citations

This map shows the geographic impact of David Clever's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Clever with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Clever more than expected).

Fields of papers citing papers by David Clever

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Clever. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Clever. The network helps show where David Clever may publish in the future.

Co-authorship network of co-authors of David Clever

This figure shows the co-authorship network connecting the top 25 collaborators of David Clever. A scholar is included among the top collaborators of David Clever based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Clever. David Clever is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ricci, Biancamaria, Jennifer Tran, Jiayu Ye, et al.. (2025). Stroma-derived Dickkopf-1 contributes to the suppression of NK cell cytotoxicity in breast cancer. Nature Communications. 16(1). 1183–1183. 4 indexed citations

Lazarides, Alexander L., Zachary D. C. Burke, David Clever, et al.. (2024). Mapping the Course of Recovery Following Limb-Salvage Surgery for Soft-Tissue Sarcoma of the Extremities. Journal of Bone and Joint Surgery. 106(19). 1797–1808.

Clever, David, et al.. (2022). The Effect of Social Deprivation on Fracture-Healing and Patient-Reported Outcomes Following Intramedullary Nailing of Tibial Shaft Fractures. Journal of Bone and Joint Surgery. 104(22). 1968–1976. 13 indexed citations

Capietto, Aude-Hélène, et al.. (2021). Effective Treatment of Established Bone Metastases Can Be Achieved by Combinatorial Osteoclast Blockade and Depletion of Granulocytic Subsets. Cancer Immunology Research. 9(12). 1400–1412. 14 indexed citations

Clever, David, et al.. (2021). Pilot Study Analysis of Serum Cytokines to Differentiate Pediatric Septic Arthritis and Transient Synovitis. Journal of Pediatric Orthopaedics. 41(10). 610–616. 2 indexed citations

Clever, David, Dustin Stwalley, Christopher M. McAndrew, et al.. (2021). In-Hospital Morbidity and Mortality With Delays in Femoral Shaft Fracture Fixation. Journal of Orthopaedic Trauma. 36(5). 239–245. 9 indexed citations

Klebanoff, Christopher A., Joseph G. Crompton, Anthony Leonardi, et al.. (2017). Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight. 2(23). 160 indexed citations

Gurusamy, Devikala, David Clever, Robert Eil, & Nicholas P. Restifo. (2017). Novel “Elements” of Immune Suppression within the Tumor Microenvironment. Cancer Immunology Research. 5(6). 426–433. 51 indexed citations

Eil, Robert, Suman K. Vodnala, David Clever, et al.. (2016). Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature. 537(7621). 539–543. 489 indexed citations breakdown →

10.

Clever, David, Rahul Roychoudhuri, Michael G. Constantinides, et al.. (2016). Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche. Cell. 166(5). 1117–1131.e14. 199 indexed citations

11.

Palmer, Douglas C., Geoffrey Guittard, Zulmarie Franco, et al.. (2015). Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. The Journal of Experimental Medicine. 212(12). 2095–2113. 139 indexed citations

12.

Sukumar, Madhusudhanan, Jie Liu, Shashank J. Patel, et al.. (2015). Modulating immunometabolism of tumor specific mouse and human lymphocytes to enhance T cell based therapy for cancer. Journal for ImmunoTherapy of Cancer. 3(S2). 1 indexed citations

13.

Eil, Robert, Rahul Roychoudhuri, David Clever, et al.. (2015). Elevated potassium levels suppress T cell activation within tumors. Journal for ImmunoTherapy of Cancer. 3(S2). 2 indexed citations

14.

Palmer, Douglas C., Geoffrey Guittard, Zulmarie Franco, et al.. (2015). Cish actively silences tcr signaling in CD8+ T cells to maintain tumor tolerance. Journal for ImmunoTherapy of Cancer. 3(S2).

15.

Crompton, Joseph G., David Clever, Raul Vizcardo, Mahendra S. Rao, & Nicholas P. Restifo. (2014). Reprogramming antitumor immunity. Trends in Immunology. 35(4). 178–185. 30 indexed citations

16.

Ji, Yun, Claudia Wrzesinski, Zhiya Yu, et al.. (2014). miR-155 augments CD8 ⁺ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic γ _c cytokines. Proceedings of the National Academy of Sciences. 112(2). 476–481. 99 indexed citations

17.

Roychoudhuri, Rahul, Kiyoshi Hirahara, Kambiz Mousavi, et al.. (2013). BACH2 represses effector programmes to stabilize Treg-mediated immune homeostasis - a new target in tumor immunotherapy?. Journal for ImmunoTherapy of Cancer. 1(S1). 1 indexed citations

18.

Benson, Don M., Courtney E. Bakan, Shuhong Zhang, et al.. (2011). IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 118(24). 6387–6391. 169 indexed citations

19.

Benson, Don M., Courtney E. Bakan, Rafat Abonour, et al.. (2010). IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data. Blood. 116(21). 1966–1966. 2 indexed citations

20.

Nettleton, David O., et al.. (1993). Swine as a model of skin inflammation. Inflammation. 17(2). 205–215. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact